Brief: SynAct Pharma Q2 Sales SEK 0
20/08/2026 06:31
BRIEF-SynAct Pharma Q2 Sales SEK 0 Aug 20 (Reuters) - SynAct Pharma Q2 cash flow from operating activities SEK -34.541 million.
- Q2 net income SEK -22.032 million
- Q2 operating expenses SEK 24.556 million
- Q2 adjusted EPS SEK -0.39
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development